Endocrine Abstracts (2013) 32 P740 | DOI: 10.1530/endoabs.32.P740

Obese hypogonadal men treated with testosterone undecanoate injections up to 5 years substantially and progressively lose weight

Farid Saad1,2, Ahmad Haider3, Gheorghe Doros4 & Abdulmaged Traish5


1Bayer Pharma AG, Berlin, Germany; 2Gulf Medical University School of Medicine, Ajman, United Arab Emirates; 3Private Urology Practice, Bremerhaven, Germany; 4Boston University School of Public Health, Boston, Massachusetts, USA; 5Boston University School of Medicine, Boston, Massachusetts, USA.


Introduction: Abdominal adipose tissue suppresses testosterone production by various mechanisms affecting the hypothalamic–pituitary–gonadal axis. Hypogonadism leads to further accumulation of fat mass thus creating a vicious circle. This study analysed the effects of restoring testosterone in obese hypogonadal men.

Methods: Cumulative, prospective, registry study of 181 men (mean age: 59.11±6.06 years) with testosterone levels below 12.1 nmol/l and a BMI of ≥30 kg/m2. All men received parenteral testosterone undecanoate 1000 mg/12 weeks following an initial 6-week interval. 89 men were treated 5 years, 114 4 years, 133 3 years, 159 2 years, 181 1 year. The changing numbers do not reflect drop-out rates but are a result of the design as new patients are added once they have received at least 1 year of treatment.

Results: At the end of the observation period, mean weight (kg) decreased from 114.71±11.59 (minimum 87.0, maximum 139.00) to 93.24±8.49 (min 80.0; max 115.0). This decrease was statistically significant vs baseline (P<0.0001) and each year compared to previous year (P<0.0001). Mean change from baseline was -16.41±0.3%. After 5 years, all men had lost any weight, 99% had lost ≥5 kg, 90% ≥10 kg, 70% ≥15 kg, and 40% ≥20 kg.

Waist circumference (cm) as a measure of abdominal fat decreased from 111.2±7.54 (min 89.00; max 129.00) to 100.47±7.11 (min 84.00; max 117.00), BMI from 36.72±3.72 (min 30.10; max 46.51) to 30.22±2.6 (min 25.66; max 36.71).

Fasting glucose decreased from 5.84±0.84 to 5.41±0.12 mmol/l, total cholesterol from 7.63±0.95 to 4.9±0.28, LDL from 4.47±1.03 to 2.94±0.93, triglycerides from 3.31±0.56 to 2.17±0.13 mmol/l. Systolic blood pressure decreased from 159.17±15.9 to 139.08±10.99 mmHg, diastolic blood pressure from 96.5±11.01 to 80.39±7.51 mmHg (P<0.0001 for all).

Conclusion: Normalising testosterone produced loss of weight/waist circumference and improved metabolic profile. These improvements were progressive over 5 years.

Article tools

My recent searches

No recent searches.